Automated N-terminal Acetylation
June 6, 2017
Synthetic peptides make promising drug candidates because their structural diversity and similiarity to endogenous peptides and proteins grants them specificity and selectivity. Unfortunately, serum proteases will rapidly break down peptides in the body, limiting their efficacy as drugs. A number of modifications have been developed to extend serum half-life, with N-terminal acetylation being one of the simplest. Synthesis of N-terminally acetylated peptides can be easily automated using the Liberty Blue.